Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
The DBV Technologies S.A. (DBVT) news page on Stock Titan aggregates company announcements, regulatory disclosures, and clinical development updates for this clinical-stage biopharmaceutical issuer. DBV Technologies focuses on food allergies and other immunologic conditions with significant unmet medical need, using its proprietary Viaskin patch technology and epicutaneous immunotherapy (EPIT) platform.
Investors and followers of DBV Technologies can use this news feed to review company-issued press releases and market announcements. Recent communications from DBV Technologies have covered topics such as progress in its Viaskin Peanut clinical program in peanut-allergic toddlers and children, including the Phase 3 VITESSE trial in children aged 4 to 7 years. The company has reported that VITESSE met its primary endpoint and that safety results were consistent with the existing Viaskin Peanut clinical program, positioning this trial as a key milestone in its development strategy.
In addition to clinical data updates, DBV Technologies news items include information on supplemental safety studies in toddlers, participation in healthcare and investor conferences, and changes in leadership and board composition. The company also releases regulated information related to its Euronext Paris listing, such as monthly disclosures of total shares and voting rights and reports on its liquidity contract.
Regulatory filings summarized in press releases, including U.S. SEC Form 8-K reports, provide insight into financial results, equity financing arrangements, and other corporate events. By following DBV Technologies news, readers can track developments in the Viaskin platform, food allergy programs, and the company’s dual listing on Euronext Paris and the Nasdaq Capital Market.
DBVT (NYSE Euronext Paris) disclosed its total shares and voting rights as of January 31, 2026 under Article 223-16 of the AMF General Regulations.
The company reported 274,852,082 total shares and a gross total of 274,852,082 voting rights, with a net total of 274,792,237 voting rights (excluding shares without voting rights).
DBV Technologies (NASDAQ:DBVT) announced €166.7 million of gross proceeds from the full exercise of ABSA Warrants and BS Warrants issued in its March 2025 financing, resulting in issuance of 59,657,507 new shares and 71,005,656 second pre-funded warrants.
Proceeds, together with existing cash, are intended to fund working capital, preparation/submission of a potential BLA and launch readiness for VIASKIN Peanut in children 4–7 in the U.S., if approved. The company estimates these funds support operations for at least 12 months and sees no substantial doubt about going concern as of the press release date.
DBVT (NYSE Euronext Paris) reports the total number of shares and voting rights as of December 31, 2025. The company confirms 235,670,864 total shares and a total gross of voting rights: 235,670,864. The total net of voting rights (excluding shares without voting rights) is 235,596,284. This document supersedes the prior publication of January 5, 2026 to reflect earlier exercises of employee stock plan instruments and warrants from a previous financing.
DBV Technologies (Nasdaq: DBVT / Euronext: DBV) published its half-year report on the liquidity contract maintained with ODDO BHF, covering July 1, 2025 to December 31, 2025 and the contract inception on July 1, 2018.
As of December 31, 2025 the liquidity account held 74,580 shares and €527,891.63. At implementation on July 1, 2018 the account held 41,159 shares and €432,367.25. From Jul 1–Dec 31, 2025 the contract executed 1,658 buys and 1,867 sales, with traded volumes of 1,496,975 shares (€3,548,323.07) on purchases and 1,632,464 shares (€3,904,915.92) on sales.
DBVT (NYSE Euronext Paris, ISIN: FR0010417345) announced the total number of shares and voting rights as of December 31, 2025 in accordance with Article 223-16 of the AMF General Regulations.
The company reported a total number of shares of 232,207,589, a total gross of voting rights of 232,207,589, and a total net of voting rights of 232,133,009 (net excludes shares without voting rights). A PDF attachment is available for the detailed statement.
DBV Technologies (Nasdaq:DBVT) announced positive topline Phase 3 VITESSE results for the VIASKIN Peanut patch in children aged 4–7. The trial met its primary endpoint: 46.6% responder rate on active vs 14.8% on placebo (difference 31.8%; 95% CI 24.5–39.0%; lower bound >15%; p=1x10-17). VITESSE enrolled 654 children (438 active, 216 placebo). Safety was consistent with prior studies: no treatment-related serious adverse events, 0.5% treatment-related anaphylaxis (n=2), discontinuations 3.2% active vs 0.5% placebo, and compliance 96.2%. A U.S. BLA submission in H1 2026 is on track. Positive topline results accelerate exercise of warrants, now exercisable through Jan 15, 2026.
Company (NYSE:DBVT) reports the total number of shares and voting rights as of November 30, 2025 under Article 223-16 of the AMF General Regulations.
As of 11/30/2025 the total number of shares is 200,777,718. The total gross voting rights equals 200,777,718 and the total net voting rights is 200,667,869 (net total excludes shares without voting rights). ISIN: FR0010417345.
DBV Technologies (NASDAQ:DBVT) announced completion of the last patient visit in the VITESSE Phase 3 trial of the VIASKIN® Peanut patch in peanut-allergic children aged 4–7 years. The double-blind, placebo-controlled treatment phase is complete and the company remains on track to report topline data in Q4 2025.
The 12-month study enrolled 654 subjects randomized 2:1 across 86 sites in the U.S., Canada, Europe, the UK, and Australia. DBV described VITESSE as the largest treatment intervention study in peanut allergy and thanked investigators, patients, and caregivers for participation.
DBV Technologies (Nasdaq: DBVT) announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11, 2025 at 2:00 p.m. ET in Boston, Massachusetts.
A live webcast will be available via the company’s Events page and an archived replay will be accessible for 90 days after the event. The presentation offers investors a direct opportunity to hear management remarks and strategic commentary.
DBV Technologies (Nasdaq: DBVT) appointed Kevin Trapp as Chief Commercial Officer, effective November 3, 2025, to lead global commercial strategy for the Viaskin® Peanut patch. DBV expects VITESSE Phase 3 topline results in Q4 2025 and plans a BLA submission for ages 4–7 in H1 2026, followed by a BLA submission for ages 1–3 in H2 2026. Mr. Trapp has 30+ years in biopharma and previously consulted for DBV since 2017.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
